2018-19和2019-20流感季节美国老年人接种三价佐剂流感疫苗与标准蛋源性四价流感疫苗的临床和经济评估

IF 5.5 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2023-12-11 DOI:10.1080/14760584.2023.2293237

Myron J. Levin, Victoria Divino, Maarten J. Postma, Stephen I. Pelton, Zifan Zhou, Mitch DeKoven, Joaquin Mould-Quevedo

引用次数: 0

摘要

临床证据支持在老年人中使用强化流感疫苗。很少有经济效果研究对添加佐剂的三价灭活疫苗（aIIV3）和标准的蛋源性四价灭活疫苗（aIIV4）进行比较。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons

Clinical evidence supports use of enhanced influenza vaccines in older adults. Few economic outcome studies have compared adjuvanted trivalent inactivated (aIIV3) and standard egg-derived quadrival...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.